Long Noncoding RNA CRNDE Promotes Proliferation of Gastric Cancer Cells by Targeting miR-145

Abstract

Background/Aims: The colorectal neoplasia differentially expressed (CRNDE) gene is a long noncoding RNA (lncRNAs) that is upregulated in colorectal cancer and glioma. Here, we investigated the regulatory function of CRNDE in gastric cancer (GC). Methods: CRNDE and miR-145 expression were assayed by qRT-PCR, and E2F3 protein expression was measured by western blotting. A luciferase reporter assay was used to detect the direct regulation of miR-145 by CRNDE. Cell viability and colony formation of human GC cells were detected using MTT and colony formation assay, respectively. Results: CRNDE was highly expressed in GC cell lines and tissues; overexpression of CRNDE increased GC cell viability and promoted colony formation. Knockdown of CRNDE did not result in loss of expression-related effects on cell proliferation and colony formation. Further investigation revealed that the miR-145 target gene E2F3 was strongly expressed following CRNDE competitive molecular sponging of miR-145. Conclusion: CRNDE acted as a growth-promoting lncRNA in GC and maybe a potential target of GC treatment.

Long noncoding RNA NEAT1‐modulated miR‐506 regulates gastric cancer development through targeting STAT3

“…10,11 miR-154 is able to repress GC cell development by inhibiting MTDH. 38 LncRNA PVT1 can act as a competing endogenous RNA by sponging miR-186 in GC. 37 Many studies have indicated the correlation between lncRNAs and F I G U R E 4 miR-506 was a direct target of NEAT1.…”

Analysis of lncRNA-Associated ceRNA Network Reveals Potential lncRNA Biomarkers in Human Colon Adenocarcinoma

“…To better understand and identify efficient new biomarkers of COAD, we are studying the mechanisms of COAD. Recent studies have shown that lncRNAs play vital roles in the development of cancer [2,3,[18][19][20][21], but there have been very few studies that focused on the profiles of lncRNAs in CRC. lncRNAs mRNA targets HOTAIR REV3L, INO80D, PHIP, AGO3, TAOK1, ATM, GPATCH2L, RC3H1, SHPRH, RICTOR, MAP3K2, ATAD2B, RIC1, PIKFYVE, WDPCP, USP34, PHC3, MIR133A1HG, BRWD1, ZBTB37 LINC00355 ATM, REV3L, GPATCH2L, RICTOR, SHPRH, PHIP, AGO3, WDPCP, INO80D, RIC1, RC3H1, TAOK1, USP34, ATAD2B, MFSD4B, FAM217A, PIKFYVE, ZBTB37, NBEAL1, GDAP2 TSSC1-IT1 SHPRH, INO80D, LRRTM2, TNRC6B, GPATCH2L, PHC3, GPR52, RC3H1, AGO3, ZBTB20, REV3L, NBEAL1, RNF169, TAS2R19, MFSD4B, IFNK, CLDN20, RIC1, FBXL13, MATR3 KCNQ1OT1 SHPRH, INO80D, AGO3, LRRTM2, RC3H1, MIR133A1HG, GPATCH2L, REV3L, MATR3, ZBTB20, PHC3, GPR52, GDAP2, POU5F2, MFSD4B, NBEAL1, TAS2R19, ATM, C1orf195, AIRN LncRNAs have sophisticated functions through diverse pathways, and the ceRNA hypothesis makes the relationship between lncRNAs, miRNAs, and mRNAs more complicated.…”

LncRNA CRNDE is a biomarker for clinical progression and poor prognosis in clear cell renal cell carcinoma

“…11 Recent years, CRNDE had been suggested to be overexpression in most types of human malignancy including colorectal cancer, 6,12-16 gastric cancer, 17 cervical cancer, 27 lung cancer, 28 and acute myeloid leukemia. 11 Recent years, CRNDE had been suggested to be overexpression in most types of human malignancy including colorectal cancer, 6,12-16 gastric cancer, 17 cervical cancer, 27 lung cancer, 28 and acute myeloid leukemia.…”